VYLUMA COMPLETES LAST PATIENT VISIT FOR PRIMARY ANALYSIS OF PIVOTAL PHASE III CHAMP STUDY EVALUATING NVK002 FOR THE TREATMENT OF MYOPIA PROGRESSION IN CHILDREN
Multi-center, international clinical study designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia
VYLUMA AND LABORATOIRES THÉA ENTER INTO LICENSING AGREEMENT FOR THE REGISTRATION AND COMMERCIALIZATION OF NVK002 IN CANADA, MEXICO, AND SELECT SOUTH AMERICAN COUNTRIES
Bridgewater, NJ, USA, June 14, 2022 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic space for the treatment of refractive errors, and Laboratoires Théa (“Théa”) announced that they have recently entered into an...
NEVAKAR INJECTABLES SELLS SIX DEVELOPMENT-STAGE, READY-TO-USE INJECTABLE PRODUCT CANDIDATES TO ENDO VENTURES LIMITED
Bridgewater, NJ, May 2, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings. Nevakar announced...
NEVAKAR INJECTABLES RECEIVES U.S. FDA APPROVAL OF READY-TO-USE EPHEDRINE INJECTION IN A PREFILLED SYRINGE
Bridgewater, NJ, USA, April 28, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, and announced...
Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
Bridgewater, NJ, USA, March 28, 2022 – Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate...
Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....
Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....
VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS
Bridgewater, NJ (October 7, 2021) – Vyluma Inc. and MyMyopiaTM (MyMyopia.com) are excited to announce new tools and resources to support the International Agency for the Prevention of Blindness (IAPB) World Sight Day, a global event to draw attention to blindness and...
VYLUMA INC LAUNCHES WITH ROBUST OPHTHALMIC PORTFOLIO, LEADING WITH A PHARMACEUTICAL TREATMENT IN PHASE III FOR MYOPIA
Bridgewater, NJ (May 25, 2021) – Vyluma Inc. announces its establishment as a wholly owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The robust pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eyedrop to slow...
NEVAKAR INC. ANNOUNCES FORMATION OF NEVAKAR INJECTABLES
Bridgewater, NJ (May 25, 2021) – Nevakar Inc. (“Nevakar”), a privately held biopharmaceutical company, today announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care,...